A new high potency active pharmaceutical ingredients unit is today being opened by Medichem at its Malta plant in Hal Far.

The company said in a statement that with this new offering it wants to consolidate its presence in the generic pharmaceutical industry.

“Our expansion to HPAI field will allow Medichem to offer a broader product portfolio to our customers. Today, 25 per cent of new drugs in development are highly potent, and we expect this tendency to keep growing”, CEO Ervin Veszprémi said.

Malta’s unique patent situation allows Medichem to develop and produce HPAI in advance of patent expiry.